The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

Necrobiosis Lipoidica Diabeticorum MarketThe global Necrobiosis Lipoidica Diabeticorum (NLD) market is expected to be worth USD 4.5 billion in 2023 and USD 8.06 billion by 2033, with a CAGR of 6% from ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

Abbott's optimistic forecasts due to high sales of glucose monitors; legal issues with Moderna and GSK; J&J's talc case ...

After hours: October 18 at 7:42 PM EDT Loading Chart for GSK ...

Teva Pharmaceutical Industries Ltd. ADR-0.06% $20.31B ...

After hours: October 18 at 7:42 PM EDT ...

FDA accepted GSK's gepotidacin application for uUTI treatment with a PDUFA date set for March 26, 2025. Gepotidacin showed superior efficacy over nitrofurantoin in EAGLE-3 trial with a 58.5% ...

How Muscle Energy Production Is Impaired in Type 2 Diabetes Oct. 9, 2024 — A new study shows that people with type 2 diabetes have lower levels of the protein that breaks down and converts ...